MA71446A - Molécules de liaison pour le traitement du cancer - Google Patents

Molécules de liaison pour le traitement du cancer

Info

Publication number
MA71446A
MA71446A MA71446A MA71446A MA71446A MA 71446 A MA71446 A MA 71446A MA 71446 A MA71446 A MA 71446A MA 71446 A MA71446 A MA 71446A MA 71446 A MA71446 A MA 71446A
Authority
MA
Morocco
Prior art keywords
binding molecules
cancer treatment
cancer
treatment
molecules
Prior art date
Application number
MA71446A
Other languages
English (en)
Inventor
Klaus-Peter Kuenkele
Srinath Kasturirangan
Andreas WERNITZNIG
Vladimir H. VOYNOV
Chao ZHENG
Juan Manuel GARCIA-MARTINEZ
Stephan Glaser
Gale Lee HANSEN
Original Assignee
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh
Publication of MA71446A publication Critical patent/MA71446A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA71446A 2022-07-15 2023-07-13 Molécules de liaison pour le traitement du cancer MA71446A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22185100 2022-07-15
EP23741704.3A EP4554677A1 (fr) 2022-07-15 2023-07-13 Molécules de liaison pour le traitement du cancer
PCT/EP2023/069513 WO2024013315A1 (fr) 2022-07-15 2023-07-13 Molécules de liaison pour le traitement du cancer

Publications (1)

Publication Number Publication Date
MA71446A true MA71446A (fr) 2025-04-30

Family

ID=82608276

Family Applications (1)

Application Number Title Priority Date Filing Date
MA71446A MA71446A (fr) 2022-07-15 2023-07-13 Molécules de liaison pour le traitement du cancer

Country Status (18)

Country Link
US (1) US20240052065A1 (fr)
EP (1) EP4554677A1 (fr)
JP (1) JP2025523031A (fr)
KR (1) KR20250039373A (fr)
CN (1) CN119630708A (fr)
AR (1) AR129931A1 (fr)
AU (1) AU2023305094A1 (fr)
CA (1) CA3259402A1 (fr)
CL (1) CL2024004082A1 (fr)
CO (1) CO2025000264A2 (fr)
DO (1) DOP2024000274A (fr)
IL (1) IL317689A (fr)
JO (1) JOP20250009A1 (fr)
MA (1) MA71446A (fr)
MX (1) MX2025000575A (fr)
PE (1) PE20250669A1 (fr)
TW (1) TW202417501A (fr)
WO (1) WO2024013315A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121426959B (zh) * 2025-12-31 2026-03-17 北京大学人民医院 一种靶向cdh3的纳米抗体及其应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
EP0281604B1 (fr) 1986-09-02 1993-03-31 Enzon Labs Inc. Molecules de liaison de chaines de polypeptide simples
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
AU634186B2 (en) 1988-11-11 1993-02-18 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
WO1993008829A1 (fr) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions induisant la destruction de cellules infectees par l'hiv
PT1498427E (pt) 1992-08-21 2010-03-22 Univ Bruxelles Imunoglobulinas desprovidas de cadeias leves
JP3720353B2 (ja) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
FI955798A7 (fi) 1993-06-03 1996-02-01 Therapeutic Antibodies Inc Terapeuttiset vasta-ainefrangmentit
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
US6323322B1 (en) 1997-04-30 2001-11-27 Enzon, Inc. Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
EP1803730A1 (fr) 2000-04-12 2007-07-04 Human Genome Sciences, Inc. Proteines de fusion d'albumine
RU2420537C2 (ru) 2001-01-17 2011-06-10 Трабьон Фармасьютикалз Инк. Слитые белки связывающий домен-иммуноглобулин
WO2004003019A2 (fr) 2002-06-28 2004-01-08 Domantis Limited Ligand
AU2002351896A1 (en) 2001-12-11 2003-06-23 Ablynx N.V. Method for displaying loops from immunoglobulin domains in different contexts
CA2471140A1 (fr) 2001-12-20 2003-07-03 Human Genome Sciences, Inc. Anticorps se liant de maniere immunospecifique a des recepteurs trail
JP2006520584A (ja) 2002-11-08 2006-09-14 アブリンクス エン．ヴェー． 安定化単一ドメイン抗体
BRPI0518151A2 (pt) 2004-10-13 2009-06-16 Ablynx Nv polipetìdeos contra amiloide-beta, ácido nucléico que codifica tal polipetìdeo, composição compreendendo tal polipetìdeo, método para produzir um polipetìdeo e uso do mesmo
CN103554260A (zh) 2005-10-12 2014-02-05 莫佛塞斯公司 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定
US8592562B2 (en) 2008-01-07 2013-11-26 Amgen Inc. Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
MX2012003598A (es) 2009-09-29 2012-04-20 Roche Glycart Ag Anticuerpos biespecificos agonistas de receptores de muerte.
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
HRP20181438T1 (hr) 2010-10-29 2018-11-16 Perseus Proteomics Inc. Protutijelo protiv cdh3 s visokom sposobnošću internaliziranja
US9127061B2 (en) * 2011-06-24 2015-09-08 Perseus Proteomics Inc. Anti-human P-cadherin (CDH3) recombinant antibody
AU2015347015B2 (en) * 2014-11-14 2019-02-14 Novartis Ag Antibody drug conjugates
MA45029B1 (fr) 2016-05-18 2021-03-31 Boehringer Ingelheim Int Anticorps anti pd-1 et anti-lag3 pour le traitement du cancer
EP3360898A1 (fr) 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Molécules bispécifiques présentant une immunoréactivité par rapport à tnf-related apoptosis-inducing ligand receptor 2 et à cadherin 17 pour le traitement du cancer

Also Published As

Publication number Publication date
CL2024004082A1 (es) 2025-05-23
CA3259402A1 (fr) 2024-01-18
EP4554677A1 (fr) 2025-05-21
JP2025523031A (ja) 2025-07-17
AU2023305094A1 (en) 2025-01-16
AR129931A1 (es) 2024-10-16
CN119630708A (zh) 2025-03-14
MX2025000575A (es) 2025-02-10
JOP20250009A1 (ar) 2025-01-14
IL317689A (en) 2025-02-01
TW202417501A (zh) 2024-05-01
US20240052065A1 (en) 2024-02-15
WO2024013315A1 (fr) 2024-01-18
CO2025000264A2 (es) 2025-01-23
KR20250039373A (ko) 2025-03-20
PE20250669A1 (es) 2025-03-04
DOP2024000274A (es) 2025-03-31

Similar Documents

Publication Publication Date Title
MA47121A (fr) Molécules de liaison pour le traitement du cancer
EP3902824A4 (fr) Molécules de liaison spécifiques de la claudine 18.2, compositions et procédés associés, pour le traitement du cancer et d'autres maladies
MA71370A (fr) Inhibiteurs macrocycliques de kras pour le traitement du cancer
MA56508A (fr) Inhibiteur d'egfr pour le traitement du cancer
MA71325A (fr) Inhibiteur de kras g12c pour le traitement du cancer
EP4373525A4 (fr) Combinaisons de traitement pour le cancer
MA52780A (fr) Inhibiteurs de kras g12c pour le traitement du cancer
EP3794038A4 (fr) Fraction de liaison pour l'activation conditionnelle de molécules d'immunoglobuline
EP3947715A4 (fr) Procédés et compositions pour le traitement du cancer
EP3894392A4 (fr) Compositions et procédés pour le traitement du cancer
EP4100061A4 (fr) Polythérapies et biomarqueurs pour le traitement du cancer
EP3621592A4 (fr) Polythérapies pour le traitement du cancer
EP3908601A4 (fr) Procédés et compositions pour le traitement du cancer
EP4263584A4 (fr) Polythérapie pour le traitement du cancer
MA71446A (fr) Molécules de liaison pour le traitement du cancer
EP4149547A4 (fr) Compositions et méthodes pour le traitement du cancer
MA71734A (fr) Composés pour le traitement du cancer
EP4087608A4 (fr) Molécules de liaison multimères hautement sialylées
MA71643A (fr) Molécules de liaison thérapeutiques
EP4110822A4 (fr) Compositions et méthodes pour traiter le cancer
EP4132489A4 (fr) Hydroxyurée-méthyl-acylfulvène pour le traitement du cancer du cerveau ou du cancer du système nerveux central
MA54501A (fr) Nouvelles protéines de liaison spécifiques de folr1 pour le diagnostic et le traitement du cancer
EP4118080C0 (fr) Modulateurs de la proteine bcl-2 dans le traitement du cancer..li 10-20 /gt
EP4174087A4 (fr) Médicament pour le traitement de tumeur
EP3917522A4 (fr) Procédés de traitement de vecteurs aav pour la céroïde-lipofuscinose neuronale infantile tardive de type 2